Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Journal Volume
35
Journal Issue
1
Date Issued
2024-01
Author(s)
Passaro, A
Wang J.
Wang, Y
Lee, S-H
Melosky, B
Azuma, K
Juan-Vidal, O
Cobo, M
Felip, E
Girard, N
Cortot, A B
Califano, R
Cappuzzo, F
Owen, S
Popat, S
Tan, J-L
Salinas, J
Tomasini, P
Gentzler, R D
William, W N
Reckamp, K L
Takahashi, T
Ganguly, S
Kowalski, D M
Bearz, A
MacKean, M
Barala, P
Bourla, A B
Girvin, A
Greger, J
Millington, D
Withelder, M
Xie, J
Sun, T
Shah, S
Diorio, B
Knoblauch, R E
Bauml, J M
Campelo, R G
Cho, B C
Abstract
Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial.
Subjects
EGFR-mutated; NSCLC; amivantamab; lazertinib; post-osimertinib
Type
journal article